India, May 19 -- Citius Pharmaceuticals Inc. (CTXR), a biopharmaceutical company, on Friday released its second quarter results from the fiscal year 2026 and provided updates on sales of its lead product LYMPHIR. Following the release, shares dropped to a 52-week low of $0.48 on Monday. LYMPHIR is a targeted immunotherapy developed by the company's subsidiary, Citius Oncology Inc. (CTOR), to treat relapsed/refractory Stage 1-3 cutaneous T-cell lymphoma (CTCL). The drug was approved by the FDA in 2024 and launched in December 2025. Q2 FY 2026: The company reported a net loss of $21.23 million or $0.95 per share, nearly doubled from the second quarter loss of $10.92 million or $1.27 per share in the previous year. The loss arose primarily fro...